僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Alemtuzumab （Campath-IH） is a humanized monoclonal antibody against CD52. Alemtuzumab does not cross-react with murine CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. Alemtuzumab is capable of complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity （ADCC）, as well as induction of apoptosis. Alemtuzumab has the potential for B-cell chronic lymphocytic leukaemia research